Novel GLP-1 analog
JP7863526B2Active Publication Date: 2026-05-21SUN PHARMACEUTICAL INDUSTRIES LTD
Patent Information
- Application Number
- JP2023045498
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-26
- Filing Date
- 2023-03-22
- Publication Date
- 2026-05-21
- Estimated Expiration
- 2039-04-05
AI Technical Summary
Technical Problem
Existing GLP-1 analogs have a short half-life and require frequent administration, leading to challenges in maintaining effective glucose control and weight management for diabetes treatment.
Method used
Development of a novel GLP-1 analog with an extended C-terminus, acylated with specific fatty acid groups via a linker, enhancing stability and duration of action, suitable for oral administration.
Benefits of technology
The novel GLP-1 analog demonstrates improved potency and prolonged action, reducing blood glucose levels and food intake, with potential for less frequent dosing and better patient adherence.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007863526000058 
Figure 0007863526000059 
Figure 0007863526000060
Abstract
To provide potent GLP-1 agonists with reduced adverse effect and improved duration of action.SOLUTION: Provided is a novel Glucagon like Peptide- 1 (GLP-1) analogs having an amino acid sequence with Leu or Ile at the C-terminal, the GLP-1 analogs having specific sequences and modifications, requiring no frequent subcutaneous administration, also being suitable for oral administration, having a stable and long duration of action, and having a potent action of GLP-1 agonist.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Novel GLP-1 analogues
JP2021520346A
Acylated GLP-1 compounds
WO2006097537A2
Extended GLP-1 compounds
WO2006097538A1
Method for making KEX1 protease sensitive polypeptides using yeast strain
WO2018178796A1